Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib or Apitolisib with Abiraterone in mCRPC
NCT01485861Phase 2Completed
- Sponsor
- Genentech
- Start
- Jan 2012
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of ipatasertib in metastatic castration-resistant prostate cancer (mCRPC) (6 arms), sponsored by Genentech. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events up to 10 months and 3 more. Started Jan 2012; status: completed.
02
Drugs
ipatasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01485861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01485861.